Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 210

    1.

    Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.

    Saloranta C, Guitard C, Pecher E, De Pablos-Velasco P, Lahti K, Brunel P, Groop L.

    Diabetes Care. 2002 Dec;25(12):2141-6.PMID: 12453951 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

    Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D.

    J Clin Endocrinol Metab. 2002 Sep;87(9):4171-6.PMID: 12213867 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

    Hanefeld M, Bouter KP, Dickinson S, Guitard C.

    Diabetes Care. 2000 Feb;23(2):202-7.PMID: 10868832 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

    Gribble FM, Manley SE, Levy JC.

    Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.

    Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T.

    Clin Transplant. 2007 Mar-Apr;21(2):246-51.PMID: 17425753 [PubMed - indexed for MEDLINE]Related articles

    6.

    Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

    Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

    Diabetes Care. 2001 Jun;24(6):983-8.PMID: 11375357 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

    Diabetes Care. 2000 Nov;23(11):1660-5.PMID: 11092289 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.

    Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.

    Diabetes Care. 2006 Feb;29(2):189-94.PMID: 16443858 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

    Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

    Diabetes Care. 2003 Jun;26(6):1685-90.PMID: 12766094 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

    Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF.

    J Clin Endocrinol Metab. 2000 Mar;85(3):1081-6.PMID: 10720043 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

    Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

    Diabetes Care. 2000 Mar;23(3):349-53.PMID: 10868864 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

    Horton ES, Foley JE, Shen SG, Baron MA.

    Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

    14.

    Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

    Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

    Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.

    Fonseca VA, Kelley DE, Cefalu W, Baron MA, Purkayastha D, Nestler JE, Hsia S, Gerich JE.

    Metabolism. 2004 Oct;53(10):1331-5. Erratum in: Metabolism. 2005 May;54(5):698. PMID: 15375790 [PubMed - indexed for MEDLINE]Related articles

    16.

    Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.

    Kalbag JB, Walter YH, Nedelman JR, McLeod JF.

    Diabetes Care. 2001 Jan;24(1):73-7.PMID: 11194245 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

    Campbell IW.

    Int J Clin Pract. 2005 Oct;59(10):1218-28. Review.PMID: 16178991 [PubMed - indexed for MEDLINE]Related articles

    18.

    A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.

    Barnett AH, Anderson DM, Shelley S, Morgan R, Owens DR.

    Diabetes Obes Metab. 2004 Mar;6(2):104-13.PMID: 14746575 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

    Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR.

    Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90.PMID: 12469362 [PubMed - indexed for MEDLINE]Related articles

    20.

    No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.

    Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, Axelsen M.

    Diabetes Metab Res Rev. 2005 Jul-Aug;21(4):376-81.PMID: 15724236 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data